SEARCH

SEARCH BY CITATION

References

  • 1
    Aw MM, Brown N, Itsuka T, Gonde CE, Adams JE, Heaton ND, et al. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl 2003; 9: 383388.
  • 2
    Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, Caron PR, et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996; 85: 921930.
  • 3
    Shaw LM, Pawinski T, Korecka M, Nawrocki A. Monitoring of mycophenolic acid in clinical transplantation. Ther Drug Monit 2002; 24: 6873.
  • 4
    van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261266.
  • 5
    Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429455.
  • 6
    Weber LT, Lamersdorf T, Shipkova M, Niedmann PD, Wiesel M, Zimmerhackl LB, et al. Area under the plasma concentration-time curve for total but not free mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in paediatric patients. Ther Drug Monit 1999; 21: 498506.
  • 7
    Jain A, Venkataramanan R, Hamad IS, Zuckerman S, Zhang S, Lever J, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001; 41: 268276.
  • 8
    Brown N, Aw MM, Mieli-Vergani G, Dhawan A, Tredger JM. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. Ther Drug Monit 2002; 24: 598606.
  • 9
    DeNofrio D, Loh E, Kao A, Korecka M, Pickering FW, Craig KA, Shaw LM. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 2000; 19: 10711076.
  • 10
    Holt DW. Monitoring mycophenolic acid. Ann Clin Biochem 2002; 39: 173183.
  • 11
    Johnston A, Holt DW. Therapeutic monitoring of immunosuppressant drugs. British J Clin Pharmacol 1999; 47: 339350.
  • 12
    Oellerich M, Shipkova M, Schütz E, Wieland E, Weber L, Tönshoff B, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. Ther Drug Monit 2000; 22: 2026.
  • 13
    Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit 2000; 22: 1419.
  • 14
    Smak Gregoor PJH, Hesse CJ, van Gelder T, van der Mast BJ, Ijzermans JNM, van Besouw NM, Weimar W. Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients. Transplant Proc 1998; 30: 11921193.
  • 15
    Nicholls AJ. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic / pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem 1998; 31: 329333.
  • 16
    Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305315.
  • 17
    Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in paediatric renal transplant recipients: a report of the German Study Group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13: 759768.
  • 18
    Meiser B, Pfeiffer M, Schmidt D, Reichenspurner H, Ueberfuhr P, Paulus D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of therapeutic drug monitoring. J Heart Lung Transplant 1999; 18: 143149.
  • 19
    Yamani MH, Starling RC, Goormastic M, Van Lente F, Smedira N, McCarthy P, Young JB. The impact of routine mycophenolate drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000; 69: 23262330.
  • 20
    Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47: 8894.
  • 21
    Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, et al. Comparison of the EMIT immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal transplant recipients on mycophenolic mofetil therapy. Clin Chem 2002; 48: 517525.
  • 22
    Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant recipients. Clin Biochem 2001; 34: 1722.
  • 23
    Kahan BD. The evolution of therapeutic immunosuppression and the potential impact of drug concentration monitoring. Ther Drug Monit 1995; 17: 560563.
  • 24
    Trull AK. Therapeutic monitoring of tacrolimus. Ann Clin Biochem 1998; 35: 167180.
  • 25
    Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Gimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 12211227.
  • 26
    Smak Gregoor PJH, van Gelder T, Hesse CJ, van der Mast BJ, van Besouw NM, Weimar W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant 1999; 14: 706708.
  • 27
    Vidal E, Cantarell C, Capdevila L, Monforte V, Roman A, Pou L. Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus. Pharmacol Toxicol 2000; 87: 182184.
  • 28
    Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000; 14: 100104.
  • 29
    Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999; 21: 3543.
  • 30
    Weber L, Schütz E, Lamersdorf T, Shipkova M, Niedmann P, Oellerich M, et al. Pharmacokinetics of mycophenolic acid (MPA) and free MPA in paediatric renal transplant recipients-a multicentre study. Nephrol Dial Transplant 1999; 14(suppl 4): 3334.
  • 31
    Shipkova M, Schutz E, Armstrong VW, Niedmann PD, Oellerich M, Wieland E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and EMIT. Clin Chem 2000; 46: 365372.
  • 32
    Cox VC, Ensom MHH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003; 25: 137157.
  • 33
    David-Neto E, Araujo LMP, Sumita NM, Mendes ME, Castro MCR, Alves CF, et al. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol 2003; 18: 266272.